Resources

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise. As a new BIA member, Emerson is committed to helping manufacturers streamline production, ensure product quality, and accelerate time to market for life-saving therapies. In this blog, David introduces the company's latest white paper.

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.

Coulter Partners successfully completed a search assignment for ExpressionEdits and is pleased to announce the placement of Dr. Amrik Basran as Chief Scientific Officer (CSO).

This week, BIA was invited by the Foreign Secretary to represent UK life sciences in Japan. In Parliament, we're championing a robust industrial strategy. Our new report provides the data and real life experience on womens’ leadership in our sector, while a former Board BIA member joins Duran Duran (sort of).

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

In this blog, Albert Maguire - King, Media and Communications Executive at the BIA, outlines how the #BIGIMPACT campaign is utilising AI, data science, and tech talent to drive breakthroughs in biotech—ensuring the UK remains at the cutting edge of healthcare and scientific progress.

Brainomix has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology.

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

This week our new BIA UK biotech financing report shows £3.5 billion invested in 2024, I detail the launch of the STVC Fellowship, look at the impact of the proposed US withdrawal from WHO, and news from Davos on groundbreaking AI-driven drug trials by Isomorphic Labs.

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

Third-Party Cyber Security (TPCS) is a cyber security firm specialising in helping growth companies assure investors, partners, and customers that cyber security is well managed within the business.

Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, has been awarded the LSX European Lifestars Award for “Healthtech Company of the Year” by HSBC Innovation Banking, and the “Most Transformative Healthtech Company of the Year” by OBN.

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.

Nxera Pharma and Antiverse have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).

Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.

Optibrium today announced the publication of a peer-reviewed study in the Journal of Computer-Aided Molecular Design

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.